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Background: Both L-4F, one apolipoprotein A-1 mimetic peptide, and statins can reduce progression of
atherosclerosis by different mechanisms. The combination of the two drugs can cause lesion regression by
rendering HDL anti-inflammatory. We postulated that combination of L-4F and simvastatin may stimulate
cholesterol efflux and related proteins expressions to alleviate atherosclerosis.
Methods: Thirty male wild-type (W-T) C57 BL/6 mice and apo E−/− mice were divided into five groups: W-T group,
atherosclerosis (AS) group, simvastatin group, L-4F group and the combination of simvastatin and L-4F group. After
16 weeks, serum lipids, atherosclerotic lesion areas, cholesterol efflux and the expressions of related proteins including
ABCA1, SR-BI, ABCG1, LXRα and PPARγ were evaluated.
Results: The aortic atherosclerotic lesion areas were reduced more significantly by combination of both drugs than
single agent, and cholesterol efflux was promoted more in combination group than simvastatin and L-4F group.
Besides, the combination group promoted expressions of cholesterol efflux related proteins.
Conclusions: The combination of L-4F and simvastatin reduced atherosclerotic lesions, which stimulates
cholesterol efflux by promoting the expressions of related proteins. In addition, these results help us further
understand that the regression of the atherosclerosis would be assessed by reduction in LDL-C with increase
of cholesterol efflux.
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StatinsBackground
Randomized clinical trials have shown that statins
reduce the progression of atherosclerosis (AS) and the
incidence of cardiovascular events. Statins are appreci-
ated and accepted by clinical staff as a first-line choice
for the treatment of coronary artery disease (CAD) in
humans. However, statins can reduce a part of car-
diovascular events in spite of lowering effectively and
efficiently low density lipoprotein cholesterol (LDL-C). So
it is high time to seek potent treatment strategy.* Correspondence: yuanyong66688@163.com
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stated.A robust inverse association between the level of high
density lipoprotein cholesterol (HDL-C) and the risk of
cardiovascular disease has fostered intensive research
seeking to target HDL metabolism for therapeutic gain
[1,2]. When it is challenging to reduce clinical CAD risk
by pharmacologic increases in HDL-C levels, the
functions of HDL are increasingly focused on, including
the ability to mediate reverse cholesterol transport
(RCT), antioxidant and anti-inflammatory capacities,
nitric oxide-promoting activity and so on. Although
cholesterol efflux from macrophages represents only a
small fraction of overall flux through the RCT pathway, it
is probably the component that is most relevant to athe-
roprotection [3]. Amit V. Khera et al. reported thatd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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inverse association with subclinical atherosclerosis and
CAD, independently of the HDL-C level. Cholesterol
efflux capacity, as an integrated measure of HDL quantity
and quality, is reflective of the role of HDL in atheropro-
tection [4]. Several lipid transporters have been showed to
promote cholesterol efflux in vitro and vivo, and the key
ones include ATP Binding Cassette A1 (ABCA1), ATP
Binding Cassette G1 (ABCG1) and Scavenger Receptor
Class B type I (SR-BI) [5-8]. Moreover, some nuclear
receptors play central roles in cholesterol metabolism,
such as Liver X receptors (LXRs) [9] and peroxisome
proliferater-activated receptors (PPARs) [10]. When acti-
vated, they induce a series of genes that are involved in
cholesterol efflux.
Apo A-1, the main protein component of HDL, plays
an essential role in anti-atherosclerosis. Apolipoprotein
A-1 mimetic peptides are made to mimic the amphi-
pathic alpha helix of ApoA-1 [11], and have the similar
functions with apoA-1. L-4F, a type of apo A-1mimetic
peptides, has a characteristic of high biological activity.
Over the last several years, studies have illustrated the
capacities of L-4F to imitate many of the protective
functions associated with ApoA-1, such as promotion of
vasodilation and anti-inflammatory effects [12,13].
Both simvastatin and apo A-1mimetic peptides can
reduce atherosclerosis by different mechanisms, and the
combination of them can promote anti-inflammatory
function of HDL and alleviate atherosclerosis. Neverthe-
less, it has not been elucidated whether they can stimu-
late cholesterol efflux and reduce atherosclerotic lesions.
Thus, we aimed to investigate the anti-atherogenic effect
of the combination of L-4F and simvastatin, and deter-
mine the mechanisms including cholesterol efflux and
the expressions of related proteins like ABCA1, SR-BI,
ABCG1, LXRα and PPARγ.
Results
Serum lipids
The results of the serum lipids (Table 1) suggested that
hypercholesterolemia model was successfully established.
Serum HDL-C levels in simva group were significantly
higher and TC, TG and LDL-C concentrations wereTable 1 Serum TC, LDL-C, HDL-C, TG and Apo A-I levels (n = 6
TC/(mmol/L) TG/(mmol/L) LD
W-T group 3.17 ± 0.532 0.91 ± 0.322
AS group 22.42 ± 1.99 2.68 ± 0.28
Simva group 14.89 ± 2.062 2.34 ± 0.171
L-4F group 20.83 ± 2.11 2.58 ± 0.27
Simva + L-4F 13.60 ± 2.502 2.25 ± 0.292
1P < 0.05, 2P < 0.001, vs. AS group; aP < 0.05, bP < 0.001, vs. Simva group.
*P < 0.05, **P < 0.001, vs. L-4F group.
TC (total cholesterol), TG (Triglycerides), LDL-C (low density lipoprotein cholesterol),significantly lower than AS group. In contrast, L-4F
group only increased the concentration of apo A-1, but
not changed other serum lipids. The combination group
increased the HDL-C and apo A-1 levels and decreased
TC, TG and LDL-C levels.
AS lesion areas
The percentage plaque area was significantly higher in
the AS group (44.30 ± 11.85%) than W-T group (2.54 ±
0.25%), which indicated that the expected atherosclerotic
model were successful. Additionally, aortic lesion area
was significantly reduced in all the treated groups
(19.77 ± 1.95%, 22.58 ± 6.88% and 12.17 ± 1.90%) com-
pared with the AS group (Figure 1).
Cholesterol efflux capacity
Compared with the W-T group (20.51 ± 1.04%), the
cholesterol efflux of atherosclerotic mice was impaired
(16.82 ± 0.39%). Simvastatin (20.55 ± 0.98%) and L-4F
(22.47 ± 1.16%) significantly increased cholesterol efflux
capacity. The combination group of simvastatin and
L-4F (25.26 ± 1.50%) promoted cholesterol efflux most
effectively (Figure 2).
mRNA expressions of ABCA1, SR-BI, ABCG1, LXRα and
PPARγ in liver and macrophage
In liver, simvastatin increased the mRNA expressions of
ABCA1, ABCG1, LXRα and PPARγ; L-4F and the com-
bination group promoted the expressions of ABCA1, SR-
BI, ABCG1, LXRα and PPARγ (Table 2). In macrophage,
we just detected the expressions of ABCA1, SR-BI and
ABCG1 because of the limited cells. The results suggested
that simvastatin just increased the expression of ABCA1
and L-4F and the combination group increased the
expressions of ABCA1 and ABCG1 (Figure 3).
Protein expressions of ABCA1, SR-BI and ABCG1 in liver
and macrophage
In liver, simvastatin increased the protein expressions of
ABCA1 and ABCG1; L-4F and the combination group
promoted the expressions of ABCA1, SR-BI and ABCG1.
In macrophage, the expression of SR-BI in all the three
treated groups was not altered. Simvastatin increased the)
L-C/(mmol/L) HDL-C/(mmol/L) Apo A-I/(mg/ml)
0.55 ± 0.102 2.27 ± 0.322 0.95 ± 0.142
12.45 ± 1.29 1.60 ± 0.22 0.73 ± 0.09
7.59 ± 1.252 2.03 ± 0.401 0.86 ± 0.10
11.75 ± 0.92 1.73 ± 0.23 0.89 ± 0.091
7.20 ± 0.682 1.99 ± 0.202 1.06 ± 0.162*
HDL-C (high density lipoprotein cholesterol).
Figure 1 Atherosclerotic lesion areas in ascending and thoracic aorta stained with Oil Red O (n = 6). a-e the aorta stained with Oil Red O
in five groups, a: W-T group; b: AS group; c: Simva group; d: L-4F group; e: Simva + L-4F group. L-4F was administered intraperitoneally daily at a
dose of 1 mg/kg/d, simvastatin intragastrically at a dose of 5 mg/kg/d and the combination group was given L-4F 1 mg/kg/d and simvastatin
5 mg/kg/d. f Lesion area was expressed as a percentage of total area. Simvastatin and L-4F equally reduced the lesion areas, and when they used
together the lesion areas were the least.1 P < 0.05, 2 P < 0.001, vs. AS group; a P < 0.05, bP < 0.001, vs. Simva group;* P < 0.05, ** P < 0.001, vs. L-4F group.
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group elevated the expressions of ABCA1 and ABCG1
(Figure 4).
Protein expressions of ABCA1, SR-BI, ABCG1, LXRα and
PPARγ in abdominal aorta
There are expressions of ABCA1, SR-BI, ABCG1, LXRα
and PPARγ in abdominal aorta in mice. SimvastatinFigure 2 Cholesterol efflux capacity from RAW264.7 cells. The
high-fat diet significantly reduced the cholesterol efflux, and
L-4F and simvastatin both improved cholesterol efflux.increased the expressions of ABCA1, ABCG1, LXRα and
PPARγ in aorta. L-4F and the combination group
promoted the expressions of ABCA1, SR-BI, ABCG1,
LXRα and PPARγ (Figure 5).
Correlation analysis
Both cholesterol efflux (r = 0.579, P < 0.001) and HDL-C
(r = 0.568, P < 0.001) were inversely correlated with AS
lesion area by Pearson correlation analysis.
Discussion
Reverse cholesterol transport (RCT) is considered to be
important in preventing the buildup of lipids that predis-
poses to atherosclerosis [14]. The process of RCT can be
divided into three stages [15]. RCT begins with cellular
cholesterol efflux to HDL from peripheral cells; Subse-
quently, the cholesterol in HDL in blood is transported
to the liver. At last, the cholesterol is delivered to
hepatocytes from HDL, and excreted through the bile.
Although cholesterol efflux from macrophages is only
the initial stage of the RCT, it has emerged as a bio-
marker of RCT. In this study, we confirmed that cho-
lesterol efflux was inversely associated with the lesion of
AS and we also believed that cholesterol efflux could
serve as a stronger predictor of AS and coronary disease
status even than serum HDL-C in different populations
Table 2 mRNA expressions of ABCA1, SR-BI, ABCG1, LXRα and PPARγ in liver
ABCA1 SR-BI ABCG1 LXRα PPARγ
W-T group 12 12 12 12 12
AS group 0.52 ± 0.08 0.64 ± 0.06 0.75 ± 0.12 0.40 ± 0.07 0.50 ± 0.08
Simva group 0.98 ± 0.14 2 0.69 ± 0.11 1.23 ± 0.192 0.71 ± 0.072 0.96 ± 0.072
L-4F group 1.38 ± 0.12 2b 1.01 ± 0.142b 1.46 ± 0.162b 1.08 ± 0.102b 1.19 ± 0.202b
Simva + L-4F 1.51 ± 0.13 2b 1.96 ± 0.492** 1.73 ± 0.242b** 1.31 ± 0.202b** 1.52 ± 0.102b**
1P < 0.05, 2P < 0.001, vs. AS group; aP < 0.05, bP < 0.001, vs. Simva group.
*P < 0.05, **P < 0.001, vs. L-4F group.
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people. The results of this study help us further under-
stand that the regression of the atherosclerotic plaque
would be observed by reduction in LDL-C together with
increase of cholesterol efflux.
Statins are largely used in patients with atherosclerosis,
and lower the rate of cardiovascular death. The majority
of trials with statins investigated patients with CAD, in
whom the reduction in cardiovascular events appeared
to be related to the cholesterol-lowering effect of statins
and ultimately to plaque stabilization [16]. However,
emerging evidence suggests that statins do more than
act as inhibitors of cholesterol biosynthesis. Many
other actions have been attributed to statins including
anti-inflammatory, anti-oxidative, anti-proliferative and
antithrombotic effects and so on [17]. In this study, we
found that simvastatin could promote cholesterol
efflux, which might be one of the mechanisms of anti-
atherosclerosis of simvastatin. It increased the expressions
of ABCA1, ABCG1, LXRα and PPARγ in liver and aorta
and ABCA1 in macrophage that probably facilitated the
cholesterol efflux. Several reports showed statins enhances
the cholesterol efflux capacity [18,19], and simvastatin
promoted the expression of hepatic genes associated with
reverse cholesterol transport [20]. However, no increase
was noted after patients had been treated with pravastatin
and atorvastatin [4]. We assumed that the discrepancy
might be partly attributable to different models.
The beneficial effects of HDL on atherosclerosis have
greatly been attributed to its major protein, apoA-I. 4 F
has the similar functions to apo A-I and high biologicalFigure 3 Fold change in mRNA levels of ABCA1, SR-BI and ABCG1 in m
the expression of SR-BI in macrophages. L-4F increased the mRNA expressi
ABCA1. 1 P < 0.05, 2 P < 0.001, vs. AS group; a P < 0.05, b P < 0.001, vs. Simvaactivity, including L-4F and D-4 F. They have the similar
functions such as reduction of lesion formation and
anti-inflammation, but L-4F is not orally efficacious
because of digestion of L-4F by gut proteases. D-4 F was
reported to stimulate cholesterol efflux [21], however it
is not determined whether L-4F has the same effect or
not. Our finding indicated L-4F improves cholesterol ef-
flux capacity. Moreover, in this experiment, we observed
for the first time that L-4F had the atheroprotective ef-
fect in parallel with simvastatin in mice. Though, of
course, its effects on humans need further research.
There are multiple pathways by which excess cholesterol
from peripheral tissue or cells can be removed by HDL
including ABCA1, ABCG1 and SR-BI. One important
pathway for cholesterol-mediated efflux involves inter-
action between ABCA1 and cholesterol-deficient and
phospholipid-depleted apo A-I complexes [22-24]. In our
research, we observed that both L-4F and simvastatin up-
regulated the expressions of ABCA1 in macrophages,
livers and aortic walls (Figure 6). That indicated that they
accelerated cholesterol removal from macrophages and
plaques and facilitated biliary excretion of cholesterol in
livers. Subsequently, ABCG1 mediates macrophage chol-
esterol efflux through interactions with spherical, cho-
lesterol -containing HDL particles, medium HDL, large
HDL, and very large HDL [6,25]. Our results inferred that
the expression of ABCG1 in macrophages, livers and
aortic walls were up-regulated by L-4F, and simvastatin in-
creased the expression of ABCG1 in livers and aortic
walls, not macrophages. ABCG1 might be expected to be
inhibitory of atherosclerosis development by promotingacrophage by RT-PCR. Simvastatin and L-4F could not change
ons ABCA1 and ABCG1, and simvastatin improved the expression of
group;* P < 0.05, ** P < 0.001, vs. L-4F group.
Figure 4 Protein expressions of ABCA1, SR-BI and ABCG1 in liver and macrophage by Western blot. Simvastatin increased the expressions
of ABCA1 and ABCG1 in liver and ABCA1 in macrophage, Both L-4F and the combination group improved the expressions of ABCA1, SR-BI
and ABCG1 in liver and ABCA1 and ABCG1 in macrophage. 1 P < 0.05, 2 P < 0.001, vs. AS group; a P < 0.05, b P < 0.001, vs. Simva group;* P < 0.05,
**P < 0.001, vs. L-4F group.
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receptor that mediates bidirectional lipid transport in the
macrophage, which is dependent on the content of cho-
lesterol in lipid-laden macrophages. The present study
suggested that L-4F up-regulated the expression of SRBI
in livers and aortic walls but not macrophages, and sim-
vastatin did not alter the expression of SR-BI. SR-BI is
known to promote cholesterol efflux from macrophage to
HDL as an acceptor [26], but this flux can be bidirectional
and has uncertain effects on macrophage cholesterol mass
which accounted for failing to up-regulate the expression
of SRBI in macrophages in our research.
At present, clinical staff shows a strong interest in
ligands for LXRS and PPARs for the treatment of cardio-
vascular disease, and they are ligand-activated transcription
factors that plays well-established roles in up-regulating
transcription of ABCA1 and ABCG1 [27,28]. Our current
study suggested that L-4F and simvastatin up-regulated the
expression of LXRα and PPARγ in livers and aorta. Several
studies have shown that synthetic LXR agonists induce
cholesterol efflux and reverse cholesterol transport by
up-regulating ABCA1 and ABCG1 expression [29,30]. LXR
agonists also improve glucose metabolism, antagonize
inflammatory responses, inhibit vascular smooth muscle
cell proliferation and protect against the development of
atherosclerosis in mice [31]. PPARs regulate diverse aspects
of lipid and glucose metabolism. Agonists for the PPARhave also been reported to increase ABCA1 and ABCG1
expression through up-regulating LXR expression [28].
D-4 F and Statins has been previously showed to cause
lesion regression by render HDL anti-inflammatory [32].
This is the first report of regression of atherosclerotic
lesions in mice administered L-4F and simvastatin by an
apparent activation of cholesterol efflux. That means the
combination of a statin and apolipoprotein A-1 mimetic
peptide can alleviate atherosclerosis by increasing the func-
tions of HDL like anti-inflammatory and cholesterol efflux.
Conclusions
In summary, our results showed that the combination of
L-4F and simvastatin can alleviate atherosclerosis more
significantly than given as single agents in mice, which
stimulates cholesterol efflux by promoting the expres-
sions of related proteins. Thus, we put forward that the
combination of simvastatin and L-4F may be a particu-
larly potent treatment strategy.
Limitations
There are limitations in extrapolating results from mur-
ine models to humans. Mice are relatively resistant to
statins [33] but respond well to 4 F [34], which may
account for the paralleled anti-atherosclerotic effect of
L-4F and simvastatin in mice. Future studies will be re-
quired to determine whether the combination of L-4F
Figure 5 Immunochemical staining of ABCA1, SR-BI, ABCG1, LXRα and PPARγ in abdominal aortic. a-y representative light microscopy
images of abdominal aorta (X400). a-e ABCA1 staining; f-j SR-BI; k-o ABCG1; p-t LXRα; u-y PPARγ.I-V statistical results of positive staining (n = 6).
1P < 0.05, 2 P < 0.001, vs. AS group; a P < 0.05, b P < 0.001, vs. Simva group;* P < 0.05, ** P < 0.001, vs. L-4F group.
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Figure 6 Deduced mechanisms by which L-4F and simvastatin promote reverse cholesterol transportation (RCT). The red arrows mean
only L-4F increases the expressions of proteins, and black arrows mean both L-4F and simvastatin up-regulate the expressions of proteins.
Neither L-4F nor simvastatin promote the expressions of proteins when it is fine dotted line.
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the present results here for mice and if so, which
regimen will be superior.
L-4F and simvastatin were showed to have the similar
anti-atherosclerotic effect, but the conclusion was
limited due to the absence of a dose–response experi-
ment to precisely prove it. However, we used the regular
dosage of each drug to compare their effects with each
other which we thought was convincing.
Our research is teamwork. In other parts of our experi-
ments, we observed that the combination of L-4F and
simvastatin significantly increased paraoxonase-1 activity,
rendered HDL anti-inflammatory, decreased Dil-Ox-LDL
influx from macrophages and reduced the concentrations
of cholesterol and cholesteryl ester in macrophages. All of
them with the results presented here may have more




Thirty 8-week-old male wild-type C57 BL/6 and apo E−/−
mice (C57 BL/6 background), purchased from Southern
Medical University institute of animals, were randomly
divided into five groups (n = 6/group) after acclimatization
for several weeks, (1) wild type (W-T) group (C57 BL/6
mice receiving vehicle and normal diet), (2) atherosclerosis(AS) group (apo E−/− mice receiving vehicle and high-
fat diet), (3) simvastatin (Simva) group (apo E−/− mice
receiving high-fat diet and simvastatin), (4)L-4F group
(apo E−/− mice receiving high-fat diet and L-4F) and (5) the
combination (Simva + L-4F) group (apo E−/− mice receiving
high-fat diet and simvastatin and L-4F). All animal studies
were performed using the protocols approved by the Insti-
tutional Animal Care and Use Committee of Southern
Medical University at Guangzhou. L-4F was administered
intraperitoneally daily at a dose of 1 mg/kg/d [12]. Peptides
L-4F contained 18 amino acids with the sequence
DWFKAFYDKVAEKFKEAF.Serum lipids analysis
Blood was collected by cardiac puncture under anesthesia
of diethyl ether after 8-h fast. Triglycerides (TG), total
cholesterol (TC), HDL-C and LDL-C were measured by
using an automated biochemical analyzer. Apo A-1 con-
centrations were determined by ELISA kit.Isolation of peritoneal macrophages
Four days after intraperitoneal thioglycollate injec-
tion, peritoneal macrophages were harvested from
the experimental mice. Following collecting, peritoneal
macrophages were immediately frozen at −80°C until
analysis.
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After the blood, peritoneal macrophage and liver
samples were taken, the aorta was cut into two sections
separately prepared for quantification of aortic lesion
area and immunohistochemistry. The ascending aorta
and thoracic aorta were then stained with Oil Red O and
lesions were quantified by video capture under a stereo
dissecting microscope. Lesion and total areas were deter-
mined using Image-Pro Plus software 6.0.
Cholesterol efflux analysis
Experiments were performed as previously described [4].
RAW264.7 cells, derived from a murine macrophage cell
line, were plated in DMEM medium supplemented with
10% fetal bovine serum and radiolabeled with 30 μg /ml
acetylated-LDL and 1 μCi/ml 3H-cholesterol (Perkin-
Elmer) for 24 h, and incubated with 0.3 mM 8-Br-cAMP
for 6 hours. Thereafter, cells were washed again and equili-
brated in DMEM medium supplemented with 2% bovine
serum albumin for 18 h. Subsequently, efflux mediums
containing 2% mice serum were added for 4 hours. Liquid
scintillation counting was used to quantify the efflux of
radioactive cholesterol from the cells. Percent efflux was
calculated by the following formula: [(microcuries of
3H-cholesterol in mediums containing mice serum −
microcuries of 3H-cholesterol in serum-free mediums) ÷
microcuries of 3H-cholesterol in cells extracted before the
efflux step] × 100.
Quantitative real-time PCR
Total RNA from mice livers and macrophages was ex-
tracted by TRIZOL Reagent (Invitrogen). cDNA synthe-
sis was performed from 1ug of total RNA using reagents
from TOYOBO. Real-time PCR was performed using a














ABCA1 (ATP Binding Cassette A1); SR-BI (Scavenger Receptor Class B type I); ABCG1 (AT
activated receptor γ).quantitative PCR was carried out on an ABI-Prism 7500
(BioRad, American) sequence detector with the defaults
settings. The primers, designed with the Primer Express
Software (Applied Biosystems) and synthesized by Invi-
trogen Ltd, were listed in Table 3. PCRs for each sample
were performed in duplicate. Relative mRNA levels were
calculated by the method of 2-△△Ct.
Western blots
Tissues and cells were harvested and protein extracts
prepared. They were then subjected to Western blot
analyses (10% SDS-PAGE; 25 μg per lane) using anti-
ABCA1, SR-BI (Novus), ABCG1, LXRα and PPARγ
(Abcam Co.Ltd, American) and β-actin antibodies. The
proteins were visualized and quantified using the Image
J analysis software program.
Abdominal aortic immunohistochemistry
All segments were embeded in paraffin and cut into
4-μm cross sections for histological examination. Expe-
riments were performed as previously described [35].
Immunostaining for ABCA1, SR-BI, ABCG1, LXRα and
PPARγ was performed in paraffin-embedded. Antibody
binding was visualized with SABC kits (Boster Biotech-
nology Co. Ltd), Diaminobenzidine (DAB) was used as
the nuclear counterstain. All sections for microscopic
quantification were captured under an Olympus BX51
light microscope equipped with a DP70 digital camera
(Olympus, Tokyo, Japan) and were measured with Image
Proplus 6.0 image analysis software.
Statistics
Data are expressed as means ± SE. Differences between
groups were evaluated using the SPSS 13.0. Groups were
compared by one-way analysis of variance (ANOVA).Sequence (5′-3′)
5′- CTT CCC ACA TTT TTG CCT GG–3′
5′- AAG GTT CCG TCC TAC CAA GTC C–3′
5′- GCA AAT TTG GCC TGT TTG TT–3′
5′- GAT CTT GCT GAG TCC GTT CC–3′
5′- CGA GAG GGC ATG TGT GAC G–3′
5′- CCG AGA AGC TAT GGC AAC C–3′
5′- TAG GGA TAG GGT TGG AGT CAG–3′
5′- AGT TTC TTC AAG CGG ATC TGT–3′
5′- ATA AAG CAT CAG GCT TCC ACT–3′
5′- GCA CTT CTG AAA CCG ACA GTA–3′
5′-CAG ATC ATG TTT GAG ACC TTC AAC–3′
5′- TCG AAG TCT AGA GCA ACA TAG CAC–3′
P Binding Cassette G1); LXRα (Liver X receptor α); PPARγ (peroxisome proliferater-
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groups using least significant difference (LSD) method
when variances are not homogeneity, and Dunnett’s T3
method when variances are homogeneity. Coefficients of
correlation (r) were calculated by Pearson correlation
analysis. A probability value of P < 0.05 was considered
to be significant.
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